Clinical trials: Noise-Induced Hearing Loss
Hearing Loss, Sensorineural, Noise Induced Hearing Loss
FX-322 in Adults With Acquired Sensorineural Hearing Loss
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural…
- Conditions
- Hearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss
- Trial name
- NCT05086276
- Testing
- FX-322
- Where
- 26 sites in United States
- Volunteers
- 142 people
- Sponsor
- Frequency Therapeutics
Tinnitus, Subjective, Tinnitus, Bilateral
Tinnitus Patient Preferences Survey
The goal of this survey is to assess several aspects related to patient preferences regarding interventions for alleviating tinnitus through invasive electrical brain stimulation (neuromodulation).
- Conditions
- Tinnitus, Subjective, Tinnitus, Bilateral, Tinnitus, Noise Induced, Tinnitus, Hearing Loss, Cochlear Implant Users
- Trial name
- NCT06782308
- Testing
- Survey using a questionnaire.
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Nicolas Gninenko
Hearing Loss, Noise-Induced, Hearing Loss
Apple Hearing Study
The Apple Hearing Study is a partnership between the University of Michigan and Apple to study sound exposure and its impact on hearing health.
- Conditions
- Hearing Loss, Noise-Induced, Hearing Loss, Tinnitus
- Trial name
- AHS (NCT04172766)
- Where
- United States
- Volunteers
- 300,000 people, healthy volunteers welcome
- Sponsor
- Apple Inc.
Sensorineural Hearing Loss, Noise Induced Hearing Loss
FX-322 in Adults With Stable Sensorineural Hearing Loss
This is a phase 2a single and repeat dose exploratory efficacy study of intratympanic FX-322 compared to placebo in healthy male and female adults with stable sensorineural hearing loss.
- Conditions
- Sensorineural Hearing Loss, Noise Induced Hearing Loss, Sudden Sensorineural Hearing Loss
- Trial name
- NCT04120116
- Testing
- FX-322 (One Dose), FX-322 (Two Doses), FX-322 (Four Doses)
- Where
- 16 sites in United States
- Volunteers
- 95 people
- Sponsor
- Frequency Therapeutics
Sensorineural Hearing Loss, Tinnitus
Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss
The HEAR-RESTORE study is an exploratory clinical research program designed to evaluate new diagnostic and regenerative approaches for individuals experiencing inner ear injury, tinnitus, and temporary or permanent hearing loss.
- Conditions
- Sensorineural Hearing Loss, Tinnitus, Acoustic Trauma, Inner Ear Injury
- Trial name
- HEAR-RESTORE (NCT07472023)
- Testing
- Audiologic Monitoring, Investigational Regenerative Pharmacologic Therapy, Stem Cell Regenerative Therapy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Truway Health, Inc.
Hearing Loss, Sensorineural, Noise Induced Hearing Loss
FX-322 in Adults With Severe Sensorineural Hearing Loss
This is a Phase 1b, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter, safety study of FX-322, administered by intratympanic injection, in adults with severe sensorineural hearing loss.
- Conditions
- Hearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss
- Trial name
- NCT04629664
- Testing
- FX-322
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Frequency Therapeutics
Hearing Loss, Sensorineural Hearing Loss
Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
This study is a single-center, randomized, placebo-controlled, double-blind, single ascending dose escalation study to determine the safety, tolerability, and PK profile of oral administration of HPN-07 in single doses to…
- Conditions
- Hearing Loss, Sensorineural Hearing Loss, Noise-Induced Hearing Loss
- Trial name
- NCT02259595
- Testing
- HPN-07, NAC
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Otologic Pharmaceutics, Inc.
Noise Exposure, Noise-induced Hearing Loss
Non-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss
The goal of this interventional clinical study is to investigate the use of mild therapeutic hypothermia devices for preservation of sensory structures in the cochlea after noise exposure. The main aims of the study are: 1.
- Conditions
- Noise Exposure, Noise-induced Hearing Loss, Noise; Adverse Effect, Mild Therapeutic Hypothermia
- Trial name
- NCT06729632
- Testing
- Cold pack-delivered mild therapeutic hypothermia
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Restorear Devices LLC
Noise-induced Hearing Loss
Protective Effects of EPI-743 on Noise-Induced Hearing Loss
If effective, administration of EPI-743 should have protective effects against temporary noise-induced hearing loss.
- Trial name
- NCT02257983
- Testing
- EPI-743
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Edison Pharmaceuticals Inc
Presbycusis, Hearing Loss, Sensorineural
FX-322 in Adults With Age-Related Sensorineural Hearing Loss
This is a Phase 1b, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter, safety study of FX-322, administered by intratympanic injection, in adults with age-related sensorineural hearing loss.
- Conditions
- Presbycusis, Hearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss
- Trial name
- NCT04601909
- Testing
- FX-322
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Frequency Therapeutics
Hearing Loss
Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
The purpose of the study is to determine whether AM-111 is effective in the treatment of acute inner ear hearing loss (acute sensorineural hearing loss, ASNHL).
- Trial name
- NCT00802425
- Testing
- AM-111
- Where
- Germany
- Volunteers
- 210 people
- Sponsor
- Auris Medical AG
Noise Induced Hearing Loss
A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss
SPI-1005 is a novel oral drug that contains a glutathione peroxidase mimetic (ebselen) that will be tested in subjects with a history of NIHL at risk for additional NIHL.
- Trial name
- PANIHL (NCT02779192)
- Testing
- SPI-1005 200mg, SPI-1005 400mg
- Where
- 5 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sound Pharmaceuticals, Incorporated